MotivationThe motivation behind my neuroscience research is to combine modern molecular and functional brain imaging approaches in an innovative multimodal way that opens up novel possibilities of integrating findings from different levels of neuronal organization in order to build systems-level models with higher explanatory value than just using imaging modalities in an additive manner.
In general, the projects address fundamental questions of how information is processed by the brain, how different levels of emotional and cognitive information processing are linked to brain metabolism, and how brain function and subjective experience changes as a result of pharmacological intervention. Epistemically, an ecological and cybernetic perspective serves as a theoretical framework to organize the empirical findings on the level of information processing and cerebral neuroenergetics according to the biological notion of homeostasis.
Insights from these basic research questions and methodological innovations are translated into clinical applications in order to describe the changes in brain region-specific neurotransmission and metabolism that characterize affective disorders such as depression, the relationship between these changes and psychopathology, and the neural and psychological responses of patients to specific compounds with high therapeutic potential.
Exploring the Antidepressant Effects of KetamineThere is growing evidence for imbalance with regard to glutamatergic neurotransmission in stress-related affective disorders. Further support for the hypothesis that dysfunctional glutamatergic signaling underlies major depressive disorder, and indeed that its reversal constitutes a potential efficacious mechanism of action, is provided by the evidence that pharmacological compounds active at the N-methyl-D-aspartate (NMDA) ionotropic glutamate receptor such as ketamine exert rapid antidepressant effects. As a tool compound ketamine enables the safe investigation of the brain region-specific effects of NMDA receptor antagonism in terms of glutamatergic neurotransmission, brain function and the association of these neural changes with emotional state, thereby allowing for increased understanding of the therapeutic mechanism of action.
Psychedelic medicines and their role in shifting the paradigm from pharmacological substitution towards transformation-based psychiatryWhile psychoactive drugs such as ketamine and psilocybin have been researched extensively in the past 30 years, scientific interest in ayahuasca just started to raise due to its potential therapeutic benefits. Beyond its traditional indigenous use in the Amazon, ayahuasca is currently spreading all over the world as an alternative plant medicine in various ritualistic contexts. This rapid dissemination coincides with the observational evidence that ayahuasca facilitates transformational processes with beneficial health outcomes.
However, solid empirical research is needed to move beyond anecdotal evidence and further verify therapeutic efficacy and biomechanisms of ayahuasca under controlled laboratory settings. In contrast to currently established pharmaceutical drugs that need to be taken on a daily basis to alleviate clinical symptoms, psychedelic medicines show considerable promise for more rapid-acting and sustainable therapeutic efficacy within only a limited number of administrations. By targeting modules of consciousness that are affected by specific disease processes, psychedelics such as ayahuasca may enhance therapeutic transformation through adaptive neuroplasticity and resetting of neurocircuitries that underlie maladaptive behaviours.
As “adaptogens” they facilitate symptom resolution through attenuation of ego-centric drives, enhanced emotion regulation capacity, cognitive flexibility, mindfulness as well as nature-relatedness in order to restore a more flexible balance between the self and the environment. Future therapeutic applications of ayahuasca and other psychedelic medicines may therefore shift the current treatment paradigm from pharmacological substitution towards more transformation-based therapies.
- Integrative psychotherapy approach based on cognitive-behavioral, systemic and psychodynamic psychotherapy, including elements of mindfulness-based, transpersonal, and humanistic psychotherapy as well as existential philosophy
- Development of psychotherapy protocols including pharmacologically induced altered states of consciousness (e.g. ayahuasca, 5-MeO-DMT, ketamine, psilocybin)
- Facilitation of neurobehavioral transformation and integration in conjunction with mindfulness-based interventions
Psychedelics & Mindfulness
- Neurobiology of expanded states of self and non-dual awareness (e.g. meditation, psychopharmacological challenge with psilocybin, 5-MeO-DMT)
- Short- and long-term benefits of psilocybin-induced mystical experiences in long-term meditation practitioners (together with Prof. Franz X. Vollenweider, Heffter Research Center Zurich, and Zen teacher Vanja Palmers)
Psychedelic Frontiers: Targeting 5-MeO-DMT (Bufo alvarius toad medicine)
- Neurobiology of non-dual states of consciousness (EEG/fMRT)
- Development of adapted inhalation and infusion-protocols for clinical applications according to GCP standards
- Clinical study: potential role in suicide prevention and to alleviate symptoms of depression, auto-aggression, addictive cravings and existential feelings of disconnection
Psychedelic Frontiers: Targeting Ayahuasca
- Global Ayahuasca Project: Anonymous online survey of short vs. long-term benefits and potential risks factors in Ayahuasca users (in collaboration with Dr. Daniel Perkins, University of Melbourne)
- Development of adapted botanical extraction procedures for clinical applications according to GCP standards
- Clinical study: efficacy of ayahuasca-based transformational psychotherapy for stress-related affective disorders (e.g. burnout, depression)
Disclaimer: The information on this website is not intended to encourage the use of ethnobotanicals or psychoactive substances. Transformational Psychotherapy specifically cautions against the use of psychedelics in violation of the law, without appropriate professional guidance and monitoring, or without careful personal evaluation of potential risks and hazards.
Bewusstseinserweiternde Substanzen als neue Möglichkeit der Therapie
Scheidegger M. Info Neurologie & Psychiatrie, Volume 6, 2017 (in press).
Cerebral mGluR5 availability contributes to elevated sleep need and behavioral adjustment after sleep deprivation.
Holst SC, Sousek A, Hefti K, Saberi-Moghadam S, Buck A, Ametamey SM, Scheidegger M, Franken P, Henning A, Seifritz E, Tafti M, Landolt HP.
Elife. 2017 Oct 5;6. pii: e28751. doi: 10.7554/eLife.28751. [Epub ahead of print]
Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans.
Bosch OG, Havranek MM, Baumberger A, Preller KH, von Rotz R, Herdener M, Kraehenmann R, Staempfli P, Scheidegger M, Klucken T, Seifritz E, Quednow BB.
Eur Neuropsychopharmacol. 2017 Apr;27(4):372-382. doi: 10.1016/j.euroneuro.2017.02.006. Epub 2017 Mar 8.
Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.
Preller KH, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M, Vollenweider FX.
Proc Natl Acad Sci U S A. 2016 May 3;113(18):5119-24. doi: 10.1073/pnas.1524187113. Epub 2016 Apr 18.
Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network.
Lehmann M, Seifritz E, Henning A, Walter M, Böker H, Scheidegger M*, Grimm S*.
Soc Cogn Affect Neurosci. 2016 Aug;11(8):1227-35. doi: 10.1093/scan/nsw034. Epub 2016 Apr 13.
Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation.
Scheidegger M, Henning A, Walter M, Lehmann M, Kraehenmann R, Boeker H, Seifritz E, Grimm S.
Hum Brain Mapp. 2016 May;37(5):1941-52. doi: 10.1002/hbm.23148. Epub 2016 Feb 25.
Effects of ketamine on cognition-emotion interaction in the brain.
Scheidegger M, Henning A, Walter M, Boeker H, Weigand A, Seifritz E, Grimm S.
Neuroimage. 2016 Jan 1;124(Pt A):8-15. doi: 10.1016/j.neuroimage.2015.08.070. Epub 2015 Sep 5.
Fast iterative pre-emphasis calibration method enabling third-order dynamic shim updated fMRI.
Fillmer A, Vannesjo SJ, Pavan M, Scheidegger M, Pruessmann KP, Henning A.
Magn Reson Med. 2016 Mar;75(3):1119-31. doi: 10.1002/mrm.25695. Epub 2015 May 7.
Glutamatergic and neurometabolic alterations in chronic cocaine users measured with (1) H-magnetic resonance spectroscopy.
Hulka LM, Scheidegger M, Vonmoos M, Preller KH, Baumgartner MR, Herdener M, Seifritz E, Henning A, Quednow BB.
Addict Biol. 2016 Jan;21(1):205-17. doi: 10.1111/adb.12217. Epub 2014 Dec 30.
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX.
Biol Psychiatry. 2015 Oct 15;78(8):572-81. doi: 10.1016/j.biopsych.2014.04.010. Epub 2014 Apr 26.
Exploring the antidepressant effects of ketamine: Insights from multimodal neuroimaging
A thesis submitted to attain the degree of Dr. sc. ETH Zurich
Scheidegger M, DISS. ETH NO. 22922, 2015.
Sleep deprivation increases dorsal nexus connectivity to the dorsolateral prefrontal cortex in humans.
Bosch OG, Rihm JS, Scheidegger M, Landolt HP, Stämpfli P, Brakowski J, Esposito F, Rasch B, Seifritz E.
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19597-602. doi: 10.1073/pnas.1317010110. Epub 2013 Nov 11.
Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans.
Hulka LM, Treyer V, Scheidegger M, Preller KH, Vonmoos M, Baumgartner MR, Johayem A, Ametamey SM, Buck A, Seifritz E, Quednow BB.
Mol Psychiatry. 2014 May;19(5):625-32. doi: 10.1038/mp.2013.51. Epub 2013 Apr 30.
Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
Scheidegger M*, Walter M*, Lehmann M, Metzger C, Grimm S, Boeker H, Boesiger P, Henning A, Seifritz E.
PLoS One. 2012;7(9):e44799. doi: 10.1371/journal.pone.0044799. Epub 2012 Sep 24.
Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep.
Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M, Berthold T, Gomez-Mancilla B, Seifritz E, Landolt HP.
Biol Psychiatry. 2013 Jan 15;73(2):161-8. doi: 10.1016/j.biopsych.2012.07.030. Epub 2012 Sep 7.